Who is succeeding Larry C. Glasscock as CEO?

Angela F. Braly will succeed Larry C. Glasscock as President and Chief Executive Officer, effective June 1, 2007. Mr. Glasscock will transition to the role of Non-Executive Chairman of the Board.

What are the key components of Angela Braly's compensation package?

Ms. Braly's compensation includes a base annual salary of $1,100,000, an annual target incentive bonus of not less than 120% of her base salary, and eligibility for equity incentive plans. The filing also details specific stock option and restricted stock unit grants awarded upon her promotion.

What is the company's plan for Mr. Glasscock's continued involvement?

Upon his retirement as CEO, Mr. Glasscock will continue to serve on the Board of Directors as the Non-Executive Chairman. He will receive specific compensation for this role, as outlined in the filing.

Are there any special provisions regarding severance for Ms. Braly?

Yes, Ms. Braly's employment agreement includes severance provisions. In the event of termination without Cause or for Good Reason, she is entitled to a severance payment of twice her base salary and target incentive bonus. This amount increases to three times her base salary and target incentive bonus if such termination occurs in connection with a Change in Control.

ELV 8-K: Leadership Changes

Summary

Elevance Health, Inc. (formerly WellPoint, Inc.) announced significant leadership changes through this Form 8-K filing on February 26, 2007. The key event is the planned succession of Angela F. Braly to President and Chief Executive Officer, effective June 1, 2007, succeeding Larry C. Glasscock who will retire from the CEO role. Mr. Glasscock will transition to a non-executive Chairman of the Board position. This transition marks a significant step in the company's executive leadership evolution. The filing also details the terms of Ms. Braly's new Employment Agreement, including her compensation package, equity awards, and severance provisions. The appointment of Ms. Braly, a long-time executive within the company, signals continuity in leadership while bringing a fresh perspective to the top executive role. Investors should note the terms of the new employment contract and the continued involvement of Mr. Glasscock in a governance capacity.

Key Highlights

1Angela F. Braly appointed President and Chief Executive Officer, effective June 1, 2007.
2Current President and CEO, Larry C. Glasscock, to retire from CEO role on June 1, 2007.
3Larry C. Glasscock will continue to serve as Non-Executive Chairman of the Board.
4Ms. Braly's new employment agreement includes a base salary of $1,100,000 and target annual bonus of at least 120% of base salary.
5Ms. Braly will receive significant equity grants, including stock options and restricted stock units (RSUs), totaling over 465,000 options and over 52,000 RSUs.
6The employment agreement outlines severance packages for termination without cause or for good reason, with enhanced provisions in the event of a Change in Control.
7Mr. Glasscock will receive specific retainers for his role as Non-Executive Chairman.

Elevance Health, Inc. 8-K Report, Executive Changes (Feb 26, 2007)

Summary

Key Highlights

Frequently Asked Questions